Kestra Medical Technologies, Ltd. - Common Stock (KMTS)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- P/B of 8.28 — trading above book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -60.3%
- Revenue growing at 115% annually
Kestra Medical Technologies, Ltd. - Common Stock (KMTS) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $1.1 billion . Key value metrics: P/B ratio 8.28, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 2 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Kestra Medical Technologies, Ltd. - Common Stock — Fundamental Analysis Summary
On financial health, KMTS shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -60.3% (sector average: -19.8%).
StockPik's composite Value Score for KMTS is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KMTS reports a solid gross margin of 48.7% (sector average: 33.5%) and a negative operating margin of -142.2%.
KMTS shows revenue growing at 115% year-over-year, with earnings declining at 21%.